Law Journal Newsletters

An ALM Website

MEDICAL MALPRACTICE LAW & STRATEGY

January 2013

Drug Marketing to Doctors: Changes May Be On the Way

By Janice G. Inman

The cornerstone of many FDA enforcement actions against pharmaceuticals manufacturers in recent years has been the charge that they have "misbranded" their pharmaceutical products by promoting them for uses not approved by the FDA. Now, the Second Circuit has thrown the concept of criminal liability for misbranding by means of off-label-use promotion into turmoil.

Log In

Subscribers: Log in below to read the full story

Already subscribe but haven't registered for all the benefits of the website?

Subscribe

Click below to subscribe to
MEDICAL MALPRACTICE LAW & STRATEGY

Subscribe

Pay-Per-View

You can purchase this article for $20.00
Click below

Purchase Article

ARTICLES FROM RELATED NEWSLETTERS

BUSINESS CRIMES BULLETIN

Loud and Clear: FinCEN Demands a Culture of Compliance

The onslaught of civil and criminal enforcement actions against financial institutions for violating anti-money laundering and counter-terrorist financing laws has continued its brisk pace in the past few months, with enforcement of the AML provisions of the Bank Secrecy Act and the sanctions regulations administered by the Office of Foreign Assets Control showing no signs of slowing down.

THE CORPORATE COUNSELOR

Jancik v. Redbox Automated Retail

Congress enacted the ADA "to remedy widespread discrimination against disabled individuals." The salutary effect of the ADA cannot be understated. However, many business owners and operators might, at the same time, rightly ask whether there are any limits to the Act's reach.

THE CORPORATE COUNSELOR

Compliance, Ethics and the Multi-generational Workforce

This article outlines two key tactics for effectively executing and nurturing a strong workplace compliance and ethics strategy. The first is fostering employee engagement. The second involves deploying the right technology tools to drive and support this.